

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 04D0467710	(X3) Date Survey Completed 07/31/2026
Name of Provider or Supplier Family Medicine Assoc Of Blytheville	Street Address, City, State 1521 N Tenth Suite C, Blytheville, AR	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	A proficiency testing desk review was performed January 14th, 2026 and the laboratory was found not in compliance with the following CONDITION LEVEL DEFICIENCIES: D2016 - 42 Code of Federal Regulations (C.F.R.) 493.803 Condition: Successful participation (proficiency testing) D6076 - 42 C.F.R. 493.1403 Condition: Laboratories performing high complexity testing; laboratory director. The following acronyms will be utilized in this report: ALB - Albumin AST - Aspartate Aminotransferase API - American Proficiency Institute CASPER - Certification and Survey Provider Enhanced Reporting CFR - Code of Federal Regulations CLIA - Clinical Laboratory Improvement Act CMS - Centers for Medicare and Medicaid Services HHS - Department of Health and Human Services TP - Total Protein TRIG - Triglycerides UA - Uric Acid
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.

	This CONDITION is not met as evidenced by: Based on review of the 2026 CMS CASPER Reports 0155D, and API records (2025-1st and 2026-2nd), the laboratory failed to achieve satisfactory performance in a proficiency program approved by the HHS for each specialty, subspecialty, and analyte or test in which the laboratory is certified under the CLIA. The laboratory failed to successfully participate in the subspecialty of Chemistry for the analytes ALB, AST, TP, TRIG, and UA. Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events is unsuccessful performance as cited at D2096.
D2096	ROUTINE CHEMISTRY CFR(s): 493.841(f) (f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the CMS CASPER Reports 0155D and API proficiency testing results, the laboratory failed to achieve satisfactory performance for two consecutive testing events (2026-1 and 2026-2) proficiency testing for the analyte ALB, AST, TP, TRIG, and UA. Survey Findings follow: A. A review of CASPER 0155D reports revealed the following results for two consecutive testing events for ALB: 2026-1: 60% 2026-2: 60% B. A review of CASPER 0155D reports revealed the following results for two consecutive testing events for AST: 2026-1: 60% 2026-2: 60% C. A review of CASPER 0155D reports revealed the following results for two consecutive testing events for TP: 2026-1: 60% 2026-2: 60% D. A review of CASPER 0155D reports revealed the following results for two consecutive testing events for TRIG: 2026-1: 60% 2026-2: 60% E. A review of CASPER 0155D reports revealed the following results for two consecutive testing events for UA 2026-1: 60% 2026-2: 60% F. A review of API records confirmed the findings.
D6000	MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493.1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on review of CMS 0155D and API proficiency testing results for 2026, the laboratory director failed to provide overall management and direction of the laboratory services. The laboratory director failed to ensure that the proficiency testing samples are tested as required under Subpart H of this part. Refer to D6016.
D6016	LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this

part;

This STANDARD is not met as evidenced by:

Based on a review of the 2026 Casper CMS 0155D and API proficiency testing event results, the laboratory director failed to ensure the laboratory successfully participated in proficiency testing in an HHS approved proficiency testing program for PT. Refer to D2096.